B4GALT2 has been reported to be involved in the immune exclusion process in lung adenocarcinoma, with its expression level negatively correlated with CD8+ T cell infiltration, and it may affect the immune therapy response by regulating the PD-1/PD-L1 pathway (43). The gene discussed is CD8A; the disease is lung adenocarcinoma.